Véronique Diéras

Jul 8, 2024 | nature.com | Sara A. Hurvitz |Kevin Kalinsky |Lisa Carey |Hope Rugo |Véronique Diéras

Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-024-00635-5, published online 25 April 2024In Table 1 of this article, the ITT column had some incorrect values. These values have now been replaced with the correct values.

Jun 5, 2024 | nature.com | Hope Rugo |Kevin Punie |Aditya Bardia |Sara A. Hurvitz |Javier Cortés |Véronique Diéras | +2 more

Correction to: npj Breast Cancer (2022) 8:98; https://doi.org/10.1038/s41523-022-00467-1, published online 29 August 2022The article includes two typographical errors, on pages 5 and 6. On page 5, in the sentence beginning with “Dose interruptions…”, and on page 6, in the sentence beginning with “A higher frequency…”, the order of the percentage of patients in the SG and TPC arms who discontinued treatment due to adverse events in the ASCENT trial has been written backwards.

Apr 24, 2024 | nature.com | Sara A. Hurvitz |Kevin Kalinsky |Lisa Carey |Hope Rugo |Véronique Diéras

AbstractIn this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients with mTNBC refractory to/relapsing after ≥2 prior chemotherapies (≥1 in the metastatic setting) were randomized 1:1 to receive SG or treatment of physician’s choice (TPC) until unacceptable toxicity/progression.

Oct 27, 2023 | high5oncology.tv | Véronique Diéras |Nadia Harbeck |Sara M. Tolaney |Giuseppe Curigliano

Our guidelines are correctStill on track for success in HER2-low MBCCan surgery be spared following primary systemic therapy? Even more new generation ADCs in breast cancer? ADC + Immunotherapy - the BEGONIA study paradigmDato-DXd - new player in advanced luminal diseaseAbemaciclib remains consistent in 5-year follow-upHighlights in mBCDATO-DX - where is it going?